<DOC>
	<DOC>NCT00240006</DOC>
	<brief_summary>To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions® and their MS Center versus those who receive support only from Shared Solutions®.</brief_summary>
	<brief_title>A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1. Males or females, 18 years of age or older. 2. Diagnosed with Relapsing Remitting Multiple Sclerosis (relapses accepted). 3. Beginning or restarting therapy with Glatiramer Acetate (Copaxone®). 4. Willing and able to complete all procedures and evaluations related to the study. 5. Willing to provide informed consent. 1. Taking any other immunomodulatory or immunosuppressant therapy in conjunction with Copaxone®. 2. Has a significant medical illness other than MS that may interfere with the assessment of endpoints or the subject's participation in the trial for the full duration of the study. 3. Any situation that the investigator or nurse (if not the investigator) feel may interfere with participation in the study. 4. Pregnant or trying to become pregnant, or breast feeding during the study. 5. Previously participated in this study or another clinical research study in the past 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Copaxone®</keyword>
	<keyword>Shared Solutions®</keyword>
</DOC>